LOGIN  |  REGISTER
C4 Therapeutics

Latest Pharma and Bio Collaborations

InterSystems and ImmunoPrecise Antibodies' Subsidiary BioStrand Collaborate to Unveil the Innovative Integration of Vector Search with LENSai for AI-Driven Healthcare Applications

March 28
Last Trade: 1.52 -0.05 -3.18

VICTORIA, British Columbia / Mar 28, 2024 / Business Wire / IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the “Company” or “IPA”) (NASDAQ: IPA), InterSystems, a creative data technology provider dedicated to helping customers solve their most critical scalability, interoperability, and speed challenges, together with ImmunoPrecise Antibodies Ltd. (IPA) (NASDAQ: IPA), an artificial intelligence-driven biotherapeutic research and technology company,...Read more


iBio and AstralBio Announce Transformative AI drug discovery Collaboration to Rapidly Develop Novel Antibodies for Obesity and Cardiometabolic Diseases

March 27
Last Trade: 4.06 0.70 20.83

Leading AI and precision biologics innovators to build a diverse set of novel best-in-class obesity treatments  iBio to use its patented generative AI/Machine Learning platform to discover, engineer and develop obesity-focused therapeutic targets  Concurrent $15M PIPE financing, announced yesterday, extends cash runway through fiscal year 2025 and provides support for collaboration  Company to host webcasted conference...Read more


Telomir Pharmaceuticals Announces Collaboration with Argenta to Study Osteoarthritis in Canines

March 26
Last Trade: 5.15 0.00 0.00

Study to determine the efficacy of Telomir-1 on mitigating the clinical signs of osteoarthritis and other age-related diseases This study is believed to be the first and only known study focused on reversing aging in canines BALTIMORE, March 26, 2024 (GLOBE NEWSWIRE) -- Telomir Pharmaceuticals, Inc. (Nasdaq:TELO) (“Telomir” or the “Company”), a pre-clinical-stage pharmaceutical company focused on the development and...Read more


Genetic Technologies Global Collaborations and Innovation Update

March 26
Last Trade: 2.89 0.08 2.85

MELBOURNE, Australia, March 26, 2024 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE, “Company”, “GTG”), a global leader in genomics-based tests in health, wellness and serious disease, is pleased to highlight a summary of the Company’s commitment to innovation. This innovation is driven by: Strong global academic relationships with research groups Continuous development of the geneType portfolio A deep...Read more


Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines

March 25
Last Trade: 2.07 -0.28 -11.91

Univercells to test proprietary mRNA vaccine delivered with Altamira’s SemaPhore™ nanoparticles Targeting safer and accessible mRNA vaccines HAMILTON, BERMUDA, March 25, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics Ltd. (“Altamira” or the “Company”) (Nasdaq:CYTO), a company providing nanoparticle-based technology for efficient RNA delivery to extrahepatic targets, today announced that it has entered into a collaboration agreement...Read more


Biodesix Announces New Master Collaborative Research Agreement with Leading US Cancer Center

March 25
Last Trade: 1.43 -0.01 -0.69

LOUISVILLE, Colo. / Mar 25, 2024 / Business Wire / Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company with a focus in lung diseases, today announced that it has entered into a new master collaborative research agreement (MCRA) with Memorial Sloan Kettering Cancer Center (MSK) under which the teams will collaborate on a development plan for diagnostic tests aimed at improving the treatment of cancer. Biodesix will utilize...Read more


Nyxoah Advances Patient Access Strategy through Partnership with the American Association of Otolaryngology – Head & Neck Surgery Foundation

March 25
Last Trade: 13.49 0.23 1.73

First medical device company to become a corporate champion at the ENTerprise Circle level Mont-Saint-Guibert, Belgium – March 25, 2024, 7:05am CET / 2:05am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has signed a strategic...Read more


Bayer and Thermo Fisher Scientific Collaborate to Increase Patient Access to Precision Cancer Medicines

March 20
Last Trade: 7.66 -0.01 -0.13

Development of next-generation sequencing companion diagnostics (CDx) Goal is to help increase patient access to Bayer’s precision cancer therapies by offering decentralized genomic testing and rapid turnaround time BERLIN & CARLSBAD, Calif.--(BUSINESS WIRE)--Bayer AG and Thermo Fisher Scientific Inc. today announced a collaboration to develop next-generation sequencing (NGS)-based companion diagnostic assays (CDx) together. These...Read more


Nascent Biotech Collaborates With Hypospray Pharma on Proprietary Transdermal Delivery System

March 19
Last Trade: 0.18 0.00 0.00

NORTH PALM BEACH, FL / ACCESSWIRE / March 19, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent", or the "Company"), a clinical-stage biotechnology Company developing monoclonal antibodies targeting various cancer types, and HypoSpray Pharma ("HypoSpray®"), a clinical and commercial stage drug delivery technology company, announced today a collaboration to develop an alternative delivery mechanism for patients who can...Read more


Centogene Extends Strategic Partnership With Takeda to Continue Providing Access to Genetic Testing for Patients With Lysosomal Storage Disorders

March 19
Last Trade: 0.71 0.02 2.90

Longstanding global partnership provides an efficient and timely diagnosis to patients with Lysosomal Storage Disorders (LSDs) CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, March 19, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the extension of an ongoing partnership with Takeda (TSE: 4502/NYSE: TAK) to...Read more


GE HealthCare Accelerates AI Innovation with Healthcare-Specific Foundation Models Powered by NVIDIA

March 18
Last Trade: 90.91 0.60 0.66

Using NVIDIA Technology, SonoSAMTrack¹ demonstrates its pliability and applicability in ultrasound image segmentation, consistently delivering high-quality results over a wide range of demanding datasets and conditions SAN JOSE, Calif. / Mar 18, 2024 / Business Wire / Building on a long-term artificial intelligence (AI) collaboration, GE HealthCare used NVIDIA technology to develop its recent research model SonoSAMTrack1, which...Read more


Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma

March 18
Last Trade: 1.19 -0.01 -0.83

SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) --  Perspective Therapeutics, Inc. (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with...Read more


SOPHiA GENETICS and The French Kidney Cancer Research Network (UroCCR) Publish Results from Multiyear Collaboration

March 15
Last Trade: 4.93 -0.33 -6.27

New Multimodal Algorithm Highlights Predictive Benefit Of Artificial Intelligence (AI) for Cancer Research BOSTON and ROLLE, Switzerland, March 15, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, and the French Kidney Cancer Research Network (UroCCR) collaborated on a study using a multimodal algorithm to help predict post-operative outcomes for those facing...Read more


GE HealthCare and Hartford HealthCare Renew and Evolve 7-Year Collaboration to Advance Patient Care and Access in Connecticut

March 14
Last Trade: 90.91 0.60 0.66

The Care Alliance agreement features a systematic approach focused on innovation, patient and staff experience, and imaging advancements through 2030 HARTFORD, Conn. / Mar 14, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and Connecticut-based Hartford HealthCare today announced that they have renewed a seven-year collaboration that...Read more


MaxHealth & The Oncology Institute Expand Value-Based Care Partnership

March 14
Last Trade: 1.58 -0.26 -14.13

CERRITOS, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology group, and MaxHealth, an innovative leader in value-based primary care, have announced a comprehensive new agreement. Under this full-risk arrangement, TOI will assume clinical and financial responsibility for all oncology care provided to patients in Pinellas, Hillsborough, Polk, Broward, and Miami-Dade...Read more


Charles River Laboratories and Navega Therapeutics Announce Comprehensive Gene Therapy Manufacturing Collaboration

March 14
Last Trade: 270.95 1.58 0.59

Next-generation AAV gene therapy to target debilitating pain disorders WILMINGTON, Mass. / Mar 14, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) and Navega Therapeutics, Inc., a biotechnology company developing epigenetic gene therapies, today announced an AAV9 production program agreement. As part of Charles River’s Cell and Gene Therapy (CGT) Accelerator Program (CAP), Navega will have access to...Read more


Hyperfine Collaborates with King’s College London to Demonstrate the Swoop® System and UNITY Project to The Princess Royal

March 12
Last Trade: 1.00 0.00 0.00

The Princess Royal was introduced to the first FDA-cleared portable MR brain imaging system being used to test the disparities in MR access in low- and medium-resource countries GUILFORD, Conn. / Mar 12, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the developer of the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop® system, today announced an exclusive demonstration of the Swoop® system and...Read more


GE HealthCare and Mass General Brigham Evolve Their AI Collaboration with Medical Imaging Foundation Models

March 12
Last Trade: 90.91 0.60 0.66

ORLANDO, Fla. / Mar 12, 2024 / Business Wire / Based on its long-term artificial intelligence (AI) partnership, GE HealthCare and Mass General Brigham plan to integrate medical imaging foundation models into their AI research work, with a strong focus on responsible AI practices. Both organizations have been working closely on AI solutions since announcing their 10-year commitment in 2017 to explore the use of AI across a broad range of...Read more


IDEAYA Biosciences Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer

March 12
Last Trade: 43.88 0.57 1.32

­Trial will evaluate IDE161, IDEAYA's investigational PARG inhibitor, in combination with KEYTRUDA® (pembrolizumab), Merck's anti-PD-1 therapy, in patients with MSI-high and MSS endometrial cancer Potential first-in-class PARG inhibitor, in combination with anti-PD-1 therapy, targets two complementary mechanisms of anti-tumor immune response in endometrial cancer IDEAYA will sponsor the clinical trial and Merck will...Read more


The American Diabetes Association and DaVita Strengthen Alliance to Tackle Chronic Disease Head-On

March 11
Last Trade: 138.05 1.20 0.88

Efforts to advance chronic disease prevention through enhanced education, awareness and support — kicking off during National Kidney Month DENVER, March 11, 2024 /PRNewswire/ -- Today, The American Diabetes Association ® (ADA) and DaVita (NYSE: DVA), a leading provider of kidney care services, announced the expansion of a multi-year collaboration, focused on advancing chronic disease prevention, specifically addressing two of...Read more


AbCellera to Collaborate with Biogen to Discover Therapeutic Antibodies for Neurological Conditions

March 11
Last Trade: 4.53 0.04 0.89

VANCOUVER, British Columbia / Mar 11, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) and Biogen Inc. (Nasdaq: BIIB) have entered into a strategic collaboration to discover antibodies for a novel target that enables the delivery of biotherapeutics to the brain for indications in neuroscience. “Delivering biologics across the blood brain barrier is one of the most important and long-standing problems in neuroscience,” said Murray...Read more


TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

March 11
Last Trade: 0.68 0.0041 0.60

BOSTON, March 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported positive proof-of-concept laboratory studies in human cells, advancing its strategic partnership with Akribion Genomics. Akribion Genomics, a German-based biotechnology start-up, is focused on a CRISPR-derived molecular complex for cancer treatment....Read more


NRx Pharmaceuticals Completes Memorandum of Understanding and Collaborations with Distribution Partners for HTX-100 (IV Ketamine)

March 11
Last Trade: 0.47 -0.06 -10.96

Company to receive first allocation of ketamine for sale by month end Partners preparing to ship IV Ketamine to full range of customers via 503a and 503b pharmacies NRx Pharmaceuticals and HOPE Therapeutics aim to provide highest quality product available to those in need and assure ongoing supply Important step toward goal of providing full suite of supply options, to ultimately include an FDA approved, and widely reimbursed,...Read more


Kyverna Therapeutics and Stanford University Agree to Evaluate KYV-101 in Patients with Non-Relapsing and Progressive Forms of Multiple Sclerosis

March 7
Last Trade: 24.84 0.00 0.00

The Investigator-Initiated Trial will assess the safety, tolerability, and clinical activity of KYV-101, a fully human anti CD19 CAR T-cell therapy in up to 12 study participants The clinical study will be supported by cutting edge correlative studies funded through a parallel research collaboration between Kyverna and Stanford University The agreements further expand the scale of ongoing clinical studies assessing the potential...Read more


Community Health Systems Partners With Mark Cuban Cost Plus Drug Company to Address the Rising Cost of Drugs and Potential Drug Shortages

March 7
Last Trade: 3.50 0.10 2.94

CHS Becomes First Health System to Purchase Drugs Manufactured by Cost Plus Drugs FRANKLIN, Tenn. / Mar 07, 2024 / Business Wire / Community Health Systems, Inc. (NYSE: CYH) (CHS) will become the first national healthcare system to purchase select pharmaceutical supplies from Mark Cuban Cost Plus Drug Company (Cost Plus Drugs) as part of a new, collaborative relationship that promises to bring high-quality, lower cost drugs into the...Read more


Avinger Announces Strategic Partnership and up to $15 Million Equity Funding Agreement with Zylox-Tonbridge

March 6
Last Trade: 3.10 0.16 5.41

Initial $7.5 Million Strategic Investment Strategic Partnership Opens Pathway to Access Greater China Market Strengthened Balance Sheet and Three-Year Extension of Existing Debt Terms REDWOOD CITY, CA / ACCESSWIRE / March 6, 2024 / Avinger, Inc. (Nasdaq:AVGR), a commercial-stage medical device company developing and marketing the first and only intravascular image-guided, catheter-based systems for diagnosis and treatment of...Read more


Gilead Sciences and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

March 6
Last Trade: 73.25 0.24 0.33

Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics Resulting from the Collaboration  FOSTER CITY, Calif. / Mar 06, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. Gilead and Merus agreed to collaborate on the...Read more


Voyageur Pharmaceuticals and Applied Pharmaceutical Innovation Forge Alliance for Carbon-Based Imaging Drug Advancement

March 4
Last Trade: 0.07 0.00 0.00

Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement (MSA). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative step forward for...Read more


DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada

March 4
Last Trade: 1.21 -0.13 -9.70

Partnership agreement will be the first-ever co-marketing and sales collaboration for the ALZET Osmotic Pumps Portfolio and Associated Product Line in the U.S. and Canada Both companies will jointly market and commercialize the ALZET product line to customers over a multi-year period CUPERTINO, Calif. , March 4, 2024 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX), today announced that it has entered into a co-marketing and...Read more


C4 Therapeutics Announces Strategic Discovery Research Collaboration with Merck KGaA, Darmstadt, Germany, Against Critical Oncogenic Proteins

March 4
Last Trade: 8.17 0.12 1.49

Collaboration Focused on Two Targeted Protein Degraders from C4T’s Internal Discovery Pipeline C4T to Receive a $16 Million Upfront Payment; Merck KGaA, Darmstadt, Germany, to Cover Discovery Research Costs Under the Collaboration C4T Eligible for up to Approximately $740 Million in Discovery, Development and Commercial Milestone Payments, in Addition to Future Royalties, Across Entire Collaboration WATERTOWN, Mass., March 04, 2024...Read more


CytoMed Therapeutics Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair

March 4
Last Trade: 2.17 -0.07 -3.12

SINGAPORE, March 04, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic therapies for the treatment of various cancers and aging-related diseases, today announced that it has entered into a Research Collaboration Agreement (“RCA”) with Sengkang...Read more


Nano-X Imaging and Beilinson Hospital Announce Collaboration to Study Diagnostic Capabilities of Nanox.ARC for Detection of Lung and Chest Diseases

February 29
Last Trade: 9.77 -0.11 -1.11

First patients in clinical study at Beilinson Hospital were scanned with the Nanox.ARC, a stationary X-ray system that produces 3D tomographic images Study may help determine clinical utility of additional information provided by tomographic imaging for a range of pulmonary conditions PETAH TIKVA, Israel, Feb. 29, 2024 (GLOBE NEWSWIRE) -- NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical...Read more


908 Devices and Cellares Collaborate to Integrate In-line Monitoring of Bioprocess Parameters into the Cell Shuttle, Cellares’ Fully Integrated Cell Therapy Manufacturing Platform

February 29
Last Trade: 7.55 0.60 8.63

BOSTON & SOUTH SAN FRANCISCO, Calif. / Feb 29, 2024 / Business Wire / 908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld and desktop devices for chemical and biochemical analysis, and Cellares, the first Integrated Development and Manufacturing Organization (IDMO) dedicated to clinical and commercial-scale cell therapy manufacturing, announce a development collaboration to integrate in-line monitoring of key cell...Read more


Wheeler Bio Seals Agreement with Charles River to Offer Portable CMC® to Discovery Clients to Accelerate Their Journey to First-in-Human Use

February 29
Last Trade: 270.95 1.58 0.59

WILMINGTON, Mass. and OKLAHOMA CITY, Feb. 29, 2024 /PRNewswire/ -- Wheeler Bio, Inc., an agile contract development and manufacturing organization (CDMO), announced today a new strategic agreement with Charles River Laboratories International, Inc. (NYSE: CRL), a global leader in pharma services, to offer Wheeler Bio's Portable CMC® (Chemistry, Manufacturing and Controls) platform to Charles River Laboratory clients. The collaboration is...Read more


Arcutis Biotherapeutics and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

February 28
Last Trade: 9.91 0.32 3.34

Arcutis to receive a $25 million upfront payment, and is eligible to receive potential development and commercial milestone payments (totaling $40 million), as well as tiered, double-digit royalties Agreement offers pathway to potentially offering a novel non-steroidal topical option to the millions of Japanese patients suffering from inflammatory skin diseases WESTLAKE VILLAGE, Calif. and TOKYO, Feb. 28, 2024 (GLOBE NEWSWIRE) --...Read more


BioMark Partners with Rubix LS to Advance Blood-Based Cancer Screening in Underserved Communities

February 28
Last Trade: 0.30 0.00 0.00

Vancouver, British Columbia--(Newsfile Corp. - February 28, 2024) - BioMark Diagnostics Inc. (CSE: BUX) (FSE: 20B) (OTC Pink: BMKDF) ("BioMark" or the "Company"), an advanced stage liquid biopsy company with a focus on hard to detect and treat cancers, and Rubix LS, a culturally competent patient medical research organization, jointly announce today the signature of a strategic partnership to develop better diagnostic tools to enhance...Read more


Dyadic Announces Strategic Partnership Agreement to Develop Affordable Rabies Prophylactics and Vaccines Using its Proprietary C1 Cell Microbial Protein Production Platform

February 28
Last Trade: 1.67 0.04 2.45

JUPITER, Fla. and BUNNIK, the Netherlands, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on applying its innovative microbial protein production platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable and accessible biopharmaceutical...Read more


Smith+Nephew and U.S. Army Institute of Surgical Research to engage in Master Cooperative Research and Development Agreement

February 28
Last Trade: 25.36 -0.98 -3.72

Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announced they have entered into a Master Cooperative Research and Development Agreement (CRADA) with the U.S. Army Institute of Surgical Research (USAISR). This marks the first time that the USAISR has entered into a master agreement of this nature with an industry-leading medical technology company. The Master CRADA represents an enterprise-wide opportunity...Read more


Viatris and Idorsia Enter Into Significant Global Research and Development Collaboration

February 28
Last Trade: 11.94 0.11 0.93

Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selatogrel and Cenerimod, Both With Blockbuster Revenue Potential Includes Future Optionality to Expand Collaboration With Additional Innovative Assets Combines Viatris' Financial Strength and Worldwide Operational Infrastructure With Idorsia's Proven, Highly Productive Drug Development Team and Innovation Engine Deal Structure...Read more


AbbVie and OSE Immunotherapeutics Announce Partnership to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation

February 28
Last Trade: 182.10 1.75 0.97

Global license and collaboration agreement to focus on the development of OSE-230, a monoclonal antibody designed to resolve chronic inflammation OSE Immunotherapeutics to receive an upfront payment of $48 million and will be eligible to receive up to an additional $665 million in milestone payments NORTH CHICAGO, Ill. and NANTES, France, Feb. 28, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and OSE Immunotherapeutics SA (ISIN:...Read more


Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

February 27
Last Trade: 21.32 -0.08 -0.37

SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National Cancer Center Hospital East (NCCHE) in Japan to study the prognostic and predictive value of molecular residual disease (MRD) testing. The SCRUM-MONSTAR-SCREEN-3 study will use Myriad’s ultra-sensitive MRD test, Precise MRD, to monitor...Read more


Benuvia Operations and Chromocell Therapeutics Announce Strategic Partnership to Advance Healthcare Solutions

February 27
Last Trade: 2.62 0.00 0.00

AUSTIN. Texas, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Benuvia Operations, LLC (“Benuvia”), a leader in pharmaceutical innovation, and Chromocell Therapeutics Corp. (“Chromocell”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment therapeutics, are pleased to announce Chromocell’s first Development and License Agreement (“Agreement”). Under the Agreement, Chromocell licensed sublingual formulation of a Diclofenac...Read more


Profound Medical in Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure

February 27
Last Trade: 8.53 0.25 3.02

TORONTO, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, today announced that it has entered into a non-exclusive collaboration with Siemens Healthineers, a global leader in medical technology. The collaboration is aimed at laying the...Read more


Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas

February 26
Last Trade: 13.89 -0.30 -2.11

Biological E. Limited (BE) to Manufacture Up to 50 Million Doses of QDENGA Per Year, Accelerating Takeda’s Ability to Deliver 100 Million Doses Per Year by 2030 At the Latest Addresses the Specific Need to Offer Multi-Dose Vials for National Immunization Programs to Help Protect the Most Vulnerable Populations Dengue Incidence Continues to Increase and Poses a Growing Threat to Public Health Worldwide CAMBRIDGE, Mass. &...Read more


Quanterix Announces First Collaborations with Five Health Networks to Aid the Diagnosis and Clinical Management of Individuals with Alzheimer’s Disease

February 26
Last Trade: 23.56 0.63 2.75

AdventHealth, Mass General Brigham, Mayo Clinic, MUSC, and UPMC will leverage Quanterix technology and assays to streamline care for Alzheimer’s patients BILLERICA, Mass. / Feb 26, 2024 / Business Wire / Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, today announced its first collaborations with health systems in pursuit of their shared goal to improve and...Read more


Humana Announces Strategic Partnership with Veda to Improve Accuracy of Provider Directories

February 26
Last Trade: 346.72 -2.78 -0.80

Enhancements will help seniors get real-time access to local in-network providers LOUISVILLE, Ky. & MADISON, Wis. / Feb 26, 2024 / Business Wire / Leading health and well-being company Humana Inc. (NYSE: HUM) today announced a strategic partnership with Veda, a health technology company specializing in helping healthcare companies solve complex provider data challenges. Humana will partner with Veda to improve the accuracy of its...Read more


GE HealthCare and Biofourmis Collaborate to Extend Patient Monitoring Outside the Hospital with Virtual Care-at-Home Solutions

February 26
Last Trade: 90.91 0.60 0.66

Collaboration supports the patient journey across the care continuum and eases transitions and care from the hospital to home CHICAGO and BOSTON, Feb. 26, 2024 /PRNewswire/ -- GE HealthCare (Nasdaq: GEHC) and Biofourmis have announced a strategic collaboration aimed at enhancing continuity of care by enabling safe, effective, and accessible care in the home to support the patient journey beyond the hospital setting. The...Read more


AbbVie and Tentarix Announce Collaboration to Develop Conditionally-Active, Multi-Specific Biologics for Oncology and Immunology

February 22
Last Trade: 182.10 1.75 0.97

Collaboration to leverage AbbVie's therapeutic area expertise and Tentarix's Tentacles™ platform, to develop novel multifunctional biologics against one target in oncology and another in immunology AbbVie will receive an exclusive option to acquire the therapeutic programs following candidate nomination by Tentarix NORTH CHICAGO, Ill. and SAN DIEGO, Feb. 22, 2024 /PRNewswire/ -- AbbVie Inc. (NYSE: ABBV) and Tentarix...Read more


Hyperfine Announces Collaboration with Athletic Heart to Provide Vital Brain Health Imaging for Former Professional Athletes

February 21
Last Trade: 1.00 0.00 0.00

The collaboration kicked off at the 2024 All-Star game in Indianapolis Athletic Heart will use the Swoop® Portable MR Imaging® system to provide brain imaging GUILFORD, Conn. & ORLANDO, Fla. / Feb 21, 2024 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the world’s first FDA-cleared portable magnetic resonance (MR) brain imaging system–the Swoop®...Read more


Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy

February 21
Last Trade: 1.03 0.04 4.03

BERKELEY, Calif. and MAINZ, Germany, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a leader in molecular genetics diagnostic solutions for early cancer detection, announced today a strategic partnership with TomaLab to launch the Company’s flagship product, ColoAlert® in Italy. TomaLab is one of Italy’s premier biotechnology laboratories and is based in Milan. The partnership...Read more


Quest Diagnostics and Instacart Collaborate to Reduce Food Insecurity Across the United States with Integrated Patient Health Coaching and Nutritious Grocery Delivery

February 21
Last Trade: 133.11 2.05 1.56

Grocery Delivery Services Now Available via Instacart to Individuals Participating in the Coaching Programs of Pack Health, a Quest Diagnostics Company, to Mitigate Social Determinants of Health Impacting Care BIRMINGHAM, Ala. and SAN FRANCISCO, Feb. 21, 2024 /PRNewswire/ -- Pack Health, a Quest Diagnostics (NYSE: DGX) company specializing in patient engagement, and Instacart (NASDAQ: CART), the leading grocery technology...Read more


Charles River Laboratories Collaborates with Pluristyx, Expanding its Portfolio of Human Pluripotent Stem Cells

February 20
Last Trade: 270.95 1.58 0.59

The addition of ES cells and iPSCs will enhance Charles River’s portfolio of powerful research tools supporting acceleration of therapeutic development. WILMINGTON, Mass. / Feb 20, 2024 / Business Wire / Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an agreement with Pluristyx Inc., a leading provider of tools, technologies, and services for the development of cell therapies. The...Read more


Carrum Health and The Oncology Institute Partner on Breast Cancer Treatment Model

February 20
Last Trade: 1.58 -0.26 -14.13

SAN FRANCISCO and LAS VEGAS, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Today, The Oncology Institute (TOI), one of the largest value-based oncology practices in the country, announced its partnership with Carrum Health. This collaboration aims to provide high-quality, cost-effective breast cancer care to patients in TOI’s Las Vegas, Nevada market, with plans for further expansion into additional markets in the coming year. Through employers,...Read more


Evaxion Biotech Announces Successful Completion of Initial Phases of Ongoing Vaccine Collaboration with MSD

February 20
Last Trade: 3.20 0.20 6.67

COPENHAGEN, Denmark, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces the successful completion of the initial phases of its vaccine collaboration with MSD (tradename of Merck & Co., Inc., Rahway, NJ, USA). The vaccine development project combines both organizations' unique...Read more


Sharps Technology Planning To Collaborate With Roncadelle To Support Global Distribution And Sales Of High Quality, Innovative, Safer Drug Delivery Systems

February 16
Last Trade: 0.34 -0.0036 -1.04

NEW YORK, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: STSS) (NASDAQ: STSSW), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, is working to create new sales and distribution opportunities through the addition of new North American 3PL partnerships to expand its reach into the global healthcare market. These additional third-party logistics...Read more


Simulations Plus Extends Collaboration with Major Toxicology Research Agency

February 15
Last Trade: 41.15 -0.20 -0.48

Research project with NIEHS includes focus on qualification of in silico methods for prioritization, assessment of risk, and identification of safety margins for chemical use LANCASTER, Calif. / Feb 15, 2024 / Business Wire / Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus”), a leading provider of modeling and simulation solutions for the pharmaceutical, biotechnology, chemicals, and consumer goods industries, today announced...Read more


Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

February 15
Last Trade: 27.51 0.49 1.81

Collaboration combines Intellia’s leading CRISPR-based platform, including its DNA writing technology, with ReCode’s proprietary Selective Organ Targeting (SORT) lipid nanoparticle (LNP) to extend the reach of gene editing to disease-causing targets in the lung CAMBRIDGE, Mass. and MENLO PARK, Calif., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on...Read more


Erasca Announces Two Clinical Trial Collaboration and Supply Agreements for Trametinib to Evaluate Naporafenib Combination in SEACRAFT-1 and SEACRAFT-2 Trials

February 14
Last Trade: 2.06 0.00 0.00

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected in H1 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on...Read more


Ono Pharmaceutical Enters into a Drug Discovery Collaboration and Option Agreement with Shattuck Labs to Generate Bifunctional Fusion Proteins

February 14
Last Trade: 8.94 -0.04 -0.45

OSAKA, Japan, Feb. 14, 2024 /PRNewswire/ -- Ono Pharmaceutical Co., Ltd. (Osaka, Japan; President and CEO: Gyo Sagara; "Ono") today announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. (Austin, Texas, USA; CEO: Taylor Schreiber; "Shattuck") to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases. Under the terms of the...Read more


Premier’s PINC AI™ Applied Sciences and Datavant Collaborate to Enable Next-Generation Clinical Trials

February 13
Last Trade: 22.10 0.30 1.38

Builds on existing partnership by further leveraging the combined power of real-world data, real-world evidence and privacy-preserving record linkage technology to help solve key clinical trial challenges. Aims to increase trial participant diversity, improve study design and operations, and advance patient experience and outcomes – while saving time and money. PHOENIX & CHARLOTTE, N.C. / Feb 13, 2024 / Business Wire / PINC...Read more


Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

February 13
Last Trade: 1.67 0.04 2.45

JUPITER, Fla. and LELAND, N.C., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Dyadic International Inc. (“Dyadic”, or the “Company”) (Nasdaq: DYAI) and Cygnus Technologies®, part of Maravai LifeSciences® (Nasdaq: MRVI), announced today a strategic partnership for the quantification of Host Cell Proteins (“HCP”) from the proprietary and patented C1-cells filamentous fungus Thermothelomyces heterothallica, (formerly Myceliophthora thermophila). Under...Read more


Lantheus Announces Collaboration to Provide Novel Tau Imaging Agent for Large Consortium Clinical Trial Sponsored by the National Institute on Aging

February 13
Last Trade: 62.24 1.78 2.94

Lantheus to supply MK-6240, an investigational F18-labeled PET imaging agent that targets tau tangles BEDFORD, Mass., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced a collaboration agreement with a National Institute on Aging...Read more


Shattuck Labs Enters into Strategic Collaboration and License Agreement with Ono Pharmaceutical to Generate Bifunctional Fusion Proteins for the Treatment of Autoimmune and Inflammatory Diseases

February 13
Last Trade: 8.94 -0.04 -0.45

AUSTIN, TX and DURHAM, NC, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bifunctional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announces a worldwide drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (Ono), to generate novel bifunctional...Read more


Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

February 13
Last Trade: 31.92 0.61 1.95

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide. The collaboration between RTD and PathAI helps advance precision medicine by bringing together...Read more


PharmAla Biotech and Red Light Holland to Collaborate on Medical Psilocybin Development

February 9
Last Trade: 0.18 0.00 0.00

VANCOUVER, British Columbia, Feb. 09, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that it has entered into a consulting relationship with Red Light Holland Corp. (“Red Light”), (CSE: TRIP) to consult on the development of...Read more


Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic Microsatellite-stabl...

February 9
Last Trade: 2.80 0.25 9.80

Interim data from additional MSS CRC patients dosed at 10 mg/kg every three weeks (Q3W) in combination with pembrolizumab anticipated in 2024 at a medical conference  Initiated evaluation of 20 mg/kg loading doses of ADG126 in combination with pembrolizumab to explore enhanced efficacy given superior therapeutic index of ADG126  Received clearance from China’s Center for Drug Evaluation (CDE) to evaluate ADG126 in...Read more


GE HealthCare and MedQuest Associates Collaborate to Provide Innovative Medical Device Technology and Digital Tools for Outpatient Imaging Centers

February 8
Last Trade: 90.91 0.60 0.66

CHICAGO / Feb 08, 2024 / Business Wire / GE HealthCare (Nasdaq: GEHC), a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator, and MedQuest Associates (MedQuest), a leading owner, operator, and manager of outpatient diagnostic imaging facilities, today announced a three-year collaboration to deliver excellence in patient care by providing access to innovative technologies from GE HealthCare and the...Read more


Inspira Technologies Collaborates with a Leading Israeli Medical Center for Clinical Evaluation of INSPIRA™ ART Device

February 8
Last Trade: 1.75 -0.01 -0.57

The parties have entered a non-binding Letter of Intent RA'ANANA, Israel, Feb. 8, 2024 /PRNewswire/ -- Inspira Technologies OXY BHN Ltd. (Nasdaq: IINN) (Nasdaq: IINNW) (the "Company" or "Inspira"), a pioneer in life support technology with a vision to supersede traditional mechanical ventilators, has announced the signing of a non-binding Letter of Intent (LOI) with Shamir Medical Center (Assaf Harofeh), a renowned...Read more


Merck Canada Announces Collaboration With Vector Institute To Further Advance Its Artificial Intelligence Capabilities And Drive Innovation In Healthcare

February 8
Last Trade: 131.95 0.20 0.15

KIRKLAND, QC, Feb. 8, 2024 /CNW/ - Merck (NYSE: MRK), known as MSD outside the United States and Canada, has entered into a multi-year agreement with the Vector Institute in Toronto, an independent not-for-profit corporation dedicated to advancing the field of artificial intelligence (AI) through world-class research.  This agreement will allow Merck Canada to gain access to Vector's exceptional research capabilities and...Read more


BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs 

February 8
Last Trade: 92.25 -0.72 -0.77

Strategic alliance leverages manufacturing and commercial infrastructure as well as technology with the aim to advance both companies’ autologous CAR-T programs towards market, pending market authorization BioNTech secures the right to utilize Autolus’ manufacturing capacity in a cost-efficient set-up to accelerate the development of BNT211 into pivotal trials in CLDN6+ tumors BioNTech to support launch and expansion of development...Read more


Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine

February 7
Last Trade: 2.71 0.02 0.74

SOUTH SAN FRANCISCO, Calif., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Standard BioTools Inc. (Nasdaq:LAB), driven by a bold purpose – Unleashing tools to accelerate breakthroughs in human health™ – today announced a collaboration agreement with Navignostics AG for development of clinical research applications and service offerings using the Hyperion XTi™ Imaging System. This collaboration is pivotal in the fight against cancer, emphasizing the...Read more


BridgeBio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan

February 7
Last Trade: 30.92 0.06 0.19

BridgeBio grants Kyowa Kirin exclusive license to develop and commercialize infigratinib for skeletal dysplasias in Japan BridgeBio to receive upfront payment of USD 100 million with royalties up to the high-twenties percent, with additional milestone-based payments Infigratinib is a once daily oral treatment option under development for achondroplasia, which was well-tolerated and demonstrated potentially best-in-class efficacy in...Read more


SOPHiA GENETICS and AstraZeneca Spain Commit to Increasing Ovarian Cancer Testing in Spain

February 7
Last Trade: 4.93 -0.33 -6.27

SOPHiA GENETICS and AstraZeneca Spain expand HRD testing program to support molecular diagnosis of ovarian cancer in Spain BOSTON and ROLLE, Switzerland and MADRID, Feb. 7, 2024 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native software company and a leader in data-driven medicine, today announced it has expanded an existing program in Spain to increase access to local testing for homologous recombination deficiency (HRD)...Read more


Jazz Pharmaceuticals Enters Definitive Agreement with Redx Pharma to Acquire Global Rights to KRAS Inhibitor Program

February 7
Last Trade: 120.42 -0.09 -0.07

Redx to receive $10 million upfront; potential for up to $870 million in development, regulatory and sales milestone payments in addition to royalties on future net sales Preclinical program expands Jazz's pipeline of targeted oncology therapies DUBLIN and ALDERLEY PARK, United Kingdom, Feb. 7, 2024 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) today announced that the companies have...Read more


Calibr-Skaggs announces expansion of option and license agreement with AbbVie to develop novel cell therapies for solid tumors and autoimmune diseases

February 6
Last Trade: 182.10 1.75 0.97

AbbVie to maintain exclusive access to Calibr-Skaggs' switchable CAR-T (sCAR-T) platform to develop novel cell therapy candidates against solid tumor targets identified by AbbVie AbbVie also has the option to explore the applicability of Calibr-Skaggs' sCAR-T platform in autoimmune diseases Calibr-Skaggs to partner with AbbVie to support discovery of next-generation sCAR-Ts using genetic medicine-based approaches LA JOLLA, Calif.,...Read more


Dyadic Announces Research and Development Collaboration Agreement with Global Biopharmaceutical Company

February 6
Last Trade: 1.67 0.04 2.45

JUPITER, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced it has signed a fully funded evaluation agreement including commercial option with an undisclosed leading global biopharmaceutical company to design and produce recombinant proteins using Dyadic's C1 filamentous fungal based microbial protein...Read more


Twist Bioscience and Element Biosciences Collaborate on Exome Sequencing Solutions for AVITI System

February 6
Last Trade: 34.31 -0.17 -0.49

Twist for Element, Exome 2.0 plus Comprehensive Exome Spike-in Workflow expected to be available soon SOUTH SAN FRANCISCO, Calif. & SAN DIEGO / Feb 06, 2024 / Business Wire / Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Element Biosciences, Inc., developer of pioneering technologies to empower science, today...Read more


Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements

February 6
Last Trade: 3.80 -0.12 -3.06

Physician-run radiation oncology innovator also to research new indications and broaden the market for SRT to include inflammatory diseases BOCA RATON, Fla., Feb. 06, 2024 (GLOBE NEWSWIRE) --  Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces a new multi-faceted...Read more


Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

February 6
Last Trade: 0.18 0.00 0.00

NORTH PALM BEACH, FL and NEW YORK, NY / ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company...Read more


Yiviva Announces Memorandum of Understanding with AstraZeneca to Develop Platforms, Technologies, and Innovative Therapeutics through a Systems Biology Approach

February 5
Last Trade: 67.75 -0.51 -0.75

NEW YORK and SHANGHAI, China, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Yiviva, a clinical-stage, platform biotechnology company developing systems biology medicines to treat aging-related diseases, signed a memorandum of understanding (MOU) with AstraZeneca China to establish a research and development collaboration at AstraZeneca’s Innovation Campus (iCampus) in Chengdu, China. The signing ceremony took place at the 2023 China International...Read more


Danaher Launches Collaboration with Cincinnati Children's Hospital Medical Center Aiming to Improve Patient Safety in Early Drug Development

February 5
Last Trade: 249.72 0.95 0.38

Danaher Beacon for Preclinical Drug Safety seeks to address major cause of failure in clinical trials Program will leverage automated liver organoid technology for drug toxicity screening Aims to expand genetic diversity of screening, accelerate therapy development, and help ensure patient safety WASHINGTON, Feb. 5, 2024 /PRNewswire/ -- Danaher Corporation (NYSE: DHR), a global science and technology innovator, today launched...Read more


Windtree Therapeutics Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research

February 1
Last Trade: 0.35 -0.01 -3.78

WARRINGTON, Pa., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing late-stage interventions for critical cardiovascular disorders, today announced that it has renewed its partnership with Chang Gung University in Taiwan to further research on SERCA2a, an important target for the Company’s cardiovascular portfolio. Windtree personnel...Read more


Takeda and Protagonist Therapeutics Enter into Worldwide License and Collaboration Agreement for Rusfertide, a Late-Stage Rare Hematology Asset

January 31
Last Trade: 28.93 0.45 1.58

Takeda Will Be Protagonist's Co-Development, U.S. Co-Commercialization Partner With 50:50 Profit Share, and With Exclusive Ex-U.S. Global Rights to Commercialize Rusfertide, Protagonist's Investigational Injectable Hepcidin Mimetic Currently in Development for the Treatment of Polycythemia Vera (PV) Takeda Will Make an Upfront Payment of $300 Million at Closing Partnership Combines Protagonist's Leadership in Pharmaceutical Peptide...Read more


Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India

January 31
Last Trade: 2.04 0.06 3.03

DUBLIN, Ireland, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Trinity Biotech plc (Nasdaq: TRIB) (the “Company”) today announced that it has entered into a non-binding Letter of Intent with Bayer for the launch of a Continuous Glucose Monitoring (“CGM”) biosensor device in China and India. This Letter of Intent is related to the Company’s recently announced acquisition of the CGM assets of Waveform Technologies, Inc.  Trinity has entered...Read more


Agilent Technologies Announces Collaboration with Incyte to Develop Advanced Companion Diagnostics in Hematology and Oncology

January 30
Last Trade: 145.51 -1.86 -1.26

SANTA CLARA, Calif. / Jan 30, 2024 / Business Wire / Agilent Technologies Inc. (NYSE: A) today announced an agreement with Incyte that will bring together Agilent’s expertise and proven track record in the development of companion diagnostics (CDx) to support the development and commercialization of Incyte’s hematology and oncology portfolio. The value of the companion diagnostics market is predicted to expand to nearly US $14B by 2030,1...Read more


MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen’s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

January 30
Last Trade: 4.19 -0.13 -3.01

ROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (Nasdaq: MXCT; LSE: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell...Read more


Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida

January 30
Last Trade: 0.72 0.03 4.14

CAPE CANAVERAL, Fla., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced a research collaboration with the University of Florida’s (UF) Center for Translational Research in Neurodegenerative Disease (CTRND) to support its work on the development of vaccines for neurodegenerative diseases. The research, funded by a grant from the state of...Read more


Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics

January 30
Last Trade: 0.02 0.00 0.00

SAN FRANCISCO, Jan. 30, 2024 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, today announced a partnership with BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, designed to advance genetics-based drug discovery for rare diseases. The goal of the collaboration is to generate new insights focused on genetic modifiers and the discovery...Read more


Becton Dickinson, Techcyte Announce Strategic Collaboration to Offer AI-Based Digital Cervical Cytology System for Pap Testing

January 30
Last Trade: 247.45 0.92 0.37

AI-Based Algorithm Aims to Enable Cytotechnologists and Pathologists to Efficiently Identify Evidence of Cervical Cancer and Precancerous Lesions FRANKLIN LAKES, N.J. and OREM, Utah, Jan. 30, 2024 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, and Techcyte, a world leader in artificial intelligence (AI)-based digital diagnostics, today announced a strategic collaboration...Read more


Gilead Sciences and Arcus Biosciences Announce Amended Collaboration and Equity Investment

January 29
Last Trade: 73.25 0.24 0.33

Investment Reinforces Companies’ Conviction in TIGIT Pathway and Provides Opportunity to Accelerate the Anti-TIGIT Program  Additional Equity Investment of $320M, Raising Gilead’s Ownership Stake in Arcus to 33%  Amendment Provides Gilead with One Additional Seat on the Arcus Board  FOSTER CITY, Calif. & HAYWARD, Calif. / Jan 29, 2024 / Business Wire / Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences,...Read more


Sign Up To Get Daily Life Science Stock News

Please review our Disclaimer and Privacy Policy before subscribing.

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

COPYRIGHT ©2023 HEALTH STOCKS HUB